Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 18, 2005. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from transactions within various employee benefit and investment plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction volumes and pricing related to employee plans.
- Share Price (GBP): £12.747 per share (used for dividend reinvestment purchases).
- Share Price (USD): $46.03 average price (for ADR fund movement).
- Dividend Date: April 7, 2005.
Material Changes
The filing reports specific movements in share holdings within employee trusts and plans:
- SmithKline Beecham Employee Share Option Plan 1991: The GSK Trust transferred 15,710 Ordinary Shares to participants on April 15, 2005.
- SmithKline Beecham Bonus Investment Plan: 1,228 Ordinary Shares were purchased via dividend reinvestment on April 15, 2005.
- GlaxoSmithKline Annual Investment Plan: 8,702 Ordinary Shares were purchased via dividend reinvestment on April 15, 2005.
- US Retirement Savings Plan: The number of Ordinary Share ADRs held by the fund decreased from 18,341,531 to 18,308,664 on April 14, 2005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory disclosure of director interests and does not contain forward-looking statements or risk assessments.
Investor Verification Checklist
- Verify the impact of the reported share transfers on total outstanding share count.
- Confirm the specific directors (Dr. J-P Garnier, Dr. T Yamada, Mr. J S Heslop) with interests in the GSK Trust and US Retirement Savings Plan.
- Review the full annual report (Form 20-F) for comprehensive financial performance data not included in this 6-K.